Overview
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
Status:
Completed
Completed
Trial end date:
2014-04-01
2014-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer. Only subjects with k-ras oncogene (KRAS) wild-type tumors are eligible. Efficacy will be assessed every 8 weeks. Treatment will be continued until progressive disease or unacceptable adverse events occur. After the end of study treatment, information on further anticancer treatment and survival will be collected every 3 months.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, GermanyCollaborator:
Merck Pte. Ltd., SingaporeTreatments:
Cetuximab
Criteria
Inclusion Criteria:Signed written informed consent
- Inpatient or outpatient subjects, 18 years of age
- Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum
- Metastatic disease (M1)
- Life expectancy of at least 12 weeks
- Presence of at least 1 measurable index lesion (not lie in an irradiated area) by
computed tomography (CT) scan or magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry
- Effective contraception for both male and female subjects if the risk of conception
exists
- White blood cell count greater than or equal to (>=) 3,000 per cubic millimeter
(/mm^3) with neutrophils >=1,500/mm3, platelet count >=100,000/mm3, hemoglobin >=5.6
millimole per liter (mmol/L) (9 gram per deciliter [g/dL])
- Total bilirubin less than or equal to (<=) 1.5 x upper reference range
- Aspartate aminotransferase (AST) <=2.5 x upper reference range, or <=5 x upper
reference range in case of liver metastasis
- Serum creatinine <=1.5 x upper reference range
- Recovery from relevant toxicity to previous treatment before study entry
- KRAS wild-type status of tumor tissue
Exclusion Criteria:
- Previous chemotherapy for colorectal cancer except adjuvant treatment if terminated >6
months before the start of treatment in this study
- Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug
in the 30 days before the start of treatment in this study
- Concurrent chronic systemic immune therapy, targeted therapy, anti-vascular
endothelial growth factor (VEGF) therapy, or epidermal growth factor receptor (EGFR-)
pathway targeting therapy not indicated in this study protocol
- Concurrent hormone therapy not indicated in this study protocol except for physiologic
replacement or contraception
- Known hypersensitivity reaction to any of the components of study treatments
- Pregnancy (absence to be confirmed by beta human choriongonadotrophin [beta-hCG] test)
or lactation period
- Brain metastasis and/or leptomeningeal disease (known or suspected)
- Clinically relevant coronary artery disease, history of myocardial infarction in the
last 12 months, or high risk of uncontrolled arrhythmia
- Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
- Peripheral neuropathy > grade 1
- Previous malignancy other than colorectal cancer in the last 5 years except basal cell
cancer of the skin or preinvasive cancer of the cervix
- Known alcohol or drug abuse
- Medical or psychological conditions that would not permit the patient to complete the
study or sign informed consent
- Participation in another clinical study within the past 30 days
- Significant disease which, in the investigator's opinion, would exclude the patient
from the study
- Legal incapacity or limited legal capacity
- KRAS mutated status of tumor tissue